- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01693666
Lifestyle Intervention Forever: Healthy Weight for Pregnancy and Birth (Pilot Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The ultimate goal of this research is to examine the impact of a healthy lifestyle intervention, targeting weight gain restriction during pregnancy in obese women (BMI≥30kg/m2), on maternal and fetal outcomes.
The overarching research program has 3 main objectives:
- To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.
- To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.
To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group.
- Maternal Outcomes: body composition; peak aerobic capacity; maternal hormonal/metabolic profiles (fasted blood sample); obstetric parameters (incidence of GDM, preeclampsia, cesarean deliveries, obstetric trauma and neonatal complications)
- Offspring Outcomes: fetal growth pattern (fetal ultrasound); neonatal anthropometry assessed ≤ 48 h of birth (crown-heel length, weight, head, chest and waist circumferences, skinfold analyses); metabolic markers at birth (cord blood); and infant anthropometry at 12 weeks of age (as above).
The experimental hypotheses to be tested are that participation in the LIFE intervention in obese pregnant women will prevent excessive weight gain and/or achieve weight maintenance (± 10 lb) during pregnancy and will result in 7-10% weight loss at 12 weeks postpartum. Secondly, we hypothesize that participation in the LIFE intervention in obese pregnant women will be associated with improved aerobic capacity, reduced incidence of obstetric complications and reduced rates of LGA as a result of beneficial alterations to metabolic intrauterine environment for fetal growth.
With regard to this IRB application, we will be conducting a pilot and feasibility trial to address the following specific aims:
- To establish the feasibility of the LIFE program as a large-scale funded project, including participant engagement in the intervention and all study visits.
- To evaluate the feasibility of the LIFE program in achieving weight maintenance and postpartum weight loss targets in obese pregnant women across all three obesity classes.
- To develop and refine the study materials for the LIFE program and assessment battery.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Saint Louis University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women aged 18-40 years with a confirmed singleton pregnancy of up to 18 weeks gestation
- Pre-pregnancy or early pregnancy BMI greater than or equal to 30 kg/m2
Exclusion Criteria:
- Aged < 18 years or > 40 years
- BMI < 30 kg/m2 at study screening
- Multiple gestations
- Previously diagnosed with type 1 or type 2 diabetes mellitus
- Subjects will be excluded from the study if they present with any absolute or relative contraindications to exercise in pregnancy (as defined by ACOG); determined by completion of medical questionnaire by supervising physician
Any evidence of:
i. Drug or alcohol abuse ii. Presence of any unstable psychiatric disorder iii. Plans to move away from the geographical area within the next nine months iv. Other medical or behavioral factors that, in the judgement of the supervising physician, may interfere with their ability to take part in a lifestyle intervention program during pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Lifestyle intervention group
The LIFE program emphasizes improved nutritional quality, moderate physical activity, and weight maintenance (±10 lb) in obese pregnant women using a contingency management (CM) approach to reinforce behavior change.
Participants will meet with the study dietitian and exercise physiologist every 2-4 weeks to develop and maintain individualized nutrition and physical activity plans, reinforced by CM.
When the subject meets with the interventionists at their regular appointments, they will review the diet and exercise requirements, and provide vouchers earned as reinforcement from the previous study period.
Diet requirements include at least 5 days of food logs each week.
Exercise requirements include objective verification of up to 5 exercise sessions per week (as prescribed).
|
|
|
NO_INTERVENTION: Routine care group
Participants in the Routine Care (RC) control group will receive no additional intervention beyond standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measurement of Gestational weight gain from study entry to delivery
Time Frame: Approx. 20-25 weeks
|
Maternal weight (lb) will be measured at program entry and at the time of delivery to determine weight gain during the study period. Pre-pregnancy body weight will be self-reported and used to estimate total gestational weight gain (lb). |
Approx. 20-25 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measure Change from baseline in maternal body composition
Time Frame: 16-21 weeks
|
Changes in lean and fat mass will be examined at study entry, in late pregnancy (34-36 weeks gestation) and at 12 weeks postpartum
|
16-21 weeks
|
|
Measure Change from baseline in maternal aerobic capacity
Time Frame: 16-21 weeks
|
Peak aerobic capacity will be examined via a standard maximal oxygen consumption (VO2max) test performed on a stationary cycle ergometer at study entry, in late pregnancy (34-36 weeks gestation), and at 12 weeks postpartum
|
16-21 weeks
|
|
Measure Maternal hormonal/metabolic changes from baseline
Time Frame: 16-21 weeks
|
A fasted blood sample will be collected at study entry, in late pregnancy (34-36 weeks gestation) and at 12 weeks postpartum to examine changes in lipid profile and adipokines (TNF-alpha, leptin).
Fasting glucose, insulin and C-peptide will also be measured and entered into the homeostatic model (HOMA) to estimate changes in insulin sensitivity and beta cell function during the study period.
|
16-21 weeks
|
|
Number of participants with Obstetric complications
Time Frame: 1-25 weeks
|
Parameters examined will include:
|
1-25 weeks
|
|
Change from baseline in maternal dietary intake
Time Frame: 16-21 weeks
|
Dietary intake will be examined at study entry (15-18 weeks gestation), in late pregnancy (34-36 weeks gestation) and at 12 weeks postpartum.
|
16-21 weeks
|
|
Measure Change from baseline in maternal psychometric outcomes
Time Frame: 16-21 weeks
|
Psychometric outcomes examined at study entry, in late pregnancy (34-36 weeks gestation) and at 12 weeks postpartum include:
|
16-21 weeks
|
|
Measure Offspring - fetal growth
Time Frame: 10-25 weeks
|
Fetal growth and abdominal circumference will be examined by fetal ultrasound at approximately 28-30, 34-36 and 38-40 weeks gestation and/or as part of routine care after 28 weeks gestation.
|
10-25 weeks
|
|
Measure Neonatal size at birth
Time Frame: Within 48 hours of birth
|
Between group comparisons of birth size will include birth weight (g), crown-heel length (mm), head circumference (mm), body mass index (kg/m2), ponderal index.
Population-specific standard deviation (SD) scores will be calculated and the incidence of small for gestational age, appropriate for gestational age and large for gestational age will be compared between groups.
|
Within 48 hours of birth
|
|
Measure Neonatal body composition at birth
Time Frame: Within 48 hours of birth
|
Neonatal lean and fat mass (g) will be calculated based on anthropometric measurements performed within 48 hours after birth
|
Within 48 hours of birth
|
|
Measure Offspring metabolic markers
Time Frame: 20-25 weeks
|
Concentrations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein-1, IGF binding protein-3, glucose, insulin, leptin and triglyceride will be examined from cord blood samples taken at the time of delivery.
|
20-25 weeks
|
|
Measure Pilot study outcomes
Time Frame: 32-37 weeks
|
The following pilot and feasibility outcomes will be assessed:
|
32-37 weeks
|
|
Measure Postpartum weight retention at 12 weeks postpartum
Time Frame: 12 weeks
|
Maternal weight (lb) will be measured at 6 & 12 weeks postpartum and compared to delivery weight (lb) to determine postpartum weight retention.
|
12 weeks
|
|
Measure Change from baseline in maternal physical activity levels
Time Frame: 16-21 weeks
|
Physical activity levels will be examined at study entry (15-18 weeks gestation), in late pregnancy (34-36 weeks gestation) and at 12 weeks postpartum.
|
16-21 weeks
|
|
Measure Infant size at 12 weeks of age
Time Frame: 12 weeks
|
Between group comparisons of body weight (g), length (mm), head circumference (mm), body mass index (kg/m2), and ponderal index.
Population-specific SD scores will be calculated and compared between groups.
|
12 weeks
|
|
Measure Infant body composition at 12 weeks of age
Time Frame: 12 weeks
|
Infant lean and fat mass (g) will be calculated based on anthropometric measurements performed at 12 weeks of age.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rosemary Catanzaro, St. Louis University
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22009 (OTHER: SLU IRB)
- 8485 (OTHER: SLU eRS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Lifestyle intervention
-
Sheba Medical CenterD-Cure, Israel; Chief Scientist, The Israel Ministry of ScienceCompleted
-
Fundación para la Lucha contra las Enfermedades...Alzheimer's AssociationCompletedAlzheimer DiseaseChile, Brazil, Argentina, Bolivia, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Peru, Puerto Rico, Uruguay
-
Northwestern UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHyperglycemia | Glucose Metabolism Disorders | Metabolic Diseases | Obesity | Diabetes Mellitus | Endocrine System Diseases | Overnutrition | Nutrition Disorders | Overweight | Body Weight | Signs and SymptomsUnited States
-
Baylor College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Michael... and other collaboratorsCompleted
-
Molde University CollegeNorwegian Labour and Welfare AdministrationCompletedObesity | Morbid Obesity | Work Related Illnesses | Life Style | Sick-leave
-
Karolinska InstitutetNot yet recruitingDepression | Anxiety | Mental Health Disorder | Psychological Distress
-
Mayo ClinicCompletedObesityUnited States
-
Laval UniversityActive, not recruitingPhysical Activity | Weight Loss | Dietary Modification | BreastfeedingCanada
-
University of AdelaideCompletedInsulin Resistance | Type 2 DiabetesAustralia
-
Umeå UniversityActive, not recruitingHypertension,Essential | Lifestyle-related ConditionSweden